Long COVID Symptoms and Treatment: What Research Currently Shows

65 Million People. No Approved Treatment. Yet.

An estimated 65 million people worldwide live with Long COVID, defined by the WHO as a condition arising in individuals with a history of SARS-CoV-2 infection, occurring at least three months after the acute illness, lasting at least two months, and not explained by an alternative diagnosis. The condition was first documented in patient accounts in early 2020, named in social media communities before formal medical recognition, and has since generated over 24,000 peer-reviewed publications. Despite this research effort, no treatment has received regulatory approval specifically for Long COVID as of 2025, and diagnostic biomarkers remain investigational. The research has, however, yielded substantial insight into what Long COVID is — and what it is not.

Defining the Condition: Criteria and Prevalence

Several competing case definitions exist, which complicates both clinical diagnosis and epidemiological comparison across studies. The WHO definition (October 2021) emphasizes symptoms occurring after confirmed or probable COVID-19 infection, lasting at least two months, not explained by alternative diagnoses. The U.S. CDC defines it as new, returning, or ongoing health problems appearing four or more weeks after acute infection.

Prevalence estimates vary widely based on case definition, follow-up duration, and whether cases were identified during pre-Omicron or Omicron-era waves. Omicron variants appear to carry lower Long COVID risk than Delta or original strains, though the sheer volume of Omicron infections has maintained high absolute case numbers.

Core Symptom Clusters

Long COVID encompasses over 200 reported symptoms across virtually every organ system. Research has identified several consistent clusters, each with distinct proposed pathophysiology.

• Fatigue and post-exertional malaise (PEM): The most commonly reported symptom; PEM — worsening of symptoms following physical or mental effort — distinguishes Long COVID fatigue from ordinary tiredness and is characteristic of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a condition Long COVID shares significant overlap with
• Cognitive impairment ("brain fog"): Reported by 20–30% of patients at 6 months; includes impaired working memory, slowed processing speed, and word-finding difficulties; objective neuropsychological testing confirms deficits in a subset of patients
• Cardiovascular symptoms: Palpitations, tachycardia, and new-onset postural orthostatic tachycardia syndrome (POTS); a 2022 study in Nature Medicine found Long COVID patients had significantly elevated risk of cardiovascular events at one year compared to matched controls
• Respiratory: Persistent dyspnea, reduced exercise tolerance, and abnormal pulmonary function tests in a subset; CT evidence of lung abnormalities in some patients beyond 12 months
• Neurological: Headache, sleep disturbance, sensory abnormalities; anosmia (loss of smell) and dysgeusia (taste disturbance) are common with some variants

Proposed Biological Mechanisms

Long COVID is not a single disease with a single mechanism. Multiple overlapping pathological processes appear to contribute in different patients, and their relative importance remains under investigation.

Treatment Landscape in 2025

No treatment has received FDA or EMA approval specifically for Long COVID. Management is currently symptom-based, and clinical trial results have been mixed.

• Paxlovid (nirmatrelvir/ritonavir) extended course: The RECOVER-VITAL trial tested a 15-day Paxlovid course; results published in 2024 showed modest benefit for some cognitive symptoms but did not meet primary endpoints overall; ongoing analysis continues
• Low-dose naltrexone: Used off-label; small observational studies report symptom improvement; mechanism may involve modulation of microglial activation; no large randomized controlled trial completed as of 2025
• Antihistamines (cetirizine + famotidine): Reported by patients and some clinicians to reduce symptoms; proposed mechanism involves mast cell activation syndrome overlap; anecdotal data only
• Rehabilitation approaches: Pacing (energy management to avoid PEM triggers) and cognitive rehabilitation have the strongest evidence base for symptom management; graded exercise therapy (GET), previously used for ME/CFS, is not recommended for Long COVID patients with PEM due to risk of symptom worsening
• SSRIs/SNRIs: Some patients report improvement in cognitive symptoms and mood; sertraline and venlafaxine are being evaluated; potential mechanism involves serotonin signaling disruption documented in Long COVID patients in 2023 Nature research

Risk Factors and Vaccination Effects

Research has identified several factors associated with higher Long COVID risk: female sex (approximately twice the incidence of males), pre-existing autoimmune conditions, higher BMI, greater number of acute symptoms during initial infection, and presence of specific autoantibodies. COVID-19 vaccination significantly reduces Long COVID risk. A meta-analysis published in The Lancet in 2023 found that two or more vaccine doses reduced Long COVID probability by approximately 50% compared to unvaccinated individuals infected with the same variant. The mechanism is likely reduced viral replication during the acute phase, limiting the immune and vascular insults that predispose to long-term sequelae. Research is slow. Patients' suffering is not.

This article is for informational purposes only. Consult a qualified healthcare professional before making medical decisions.